Intra-cellular Therapies, Inc. (ITCI) Technical Analysis
$86.00▲0.89%
Market is closed - opens 8 PM, 27 Dec 2024
Insights
- Intra-cellular Therapies is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Intra-cellular Therapies stock suggests that it is range bound and no decision can be made based on this information
- Based on analysis of the Moving Averages technical indicator, Intra-cellular Therapies stock is in a uptrend ↗️
- Based on analysis of the Pivot Points, the current market trend for Intra-cellular Therapies stock suggests that it is a good time to buy
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 52.49 | Neutral |
Stochastic | 49.94, 36.91 | Neutral |
Ultimate Oscillator | 52.16 | Neutral |
Stochastic Relative Strength Index | 28.22, 29.34 | Neutral |
Moving Average Convergence Divergence | 0.15, 0.29 | Sell |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 84.59 | Sell |
20 | 84.93 | Buy |
50 | 83.82 | Buy |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 84.7 | Sell |
20 | 84.73 | Buy |
50 | 83.26 | Buy |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 84.8 | Neutral |
20 | 84.97 | Neutral |
50 | 84.19 | Neutral |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 84.6 | Sell |
20 | 85.0 | Sell |
50 | 86.1 | Buy |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 84.65 | Buy |
20 | 84.22 | Sell |
50 | 86.64 | Buy |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 86.12 |
Resistance L2 | 85.32 |
Resistance L1 | 84.66 |
Pivot Point | 83.86 |
Support L1 | 83.2 |
Support L2 | 82.4 |
Support L3 | 81.74 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.